Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 5/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085752 | 0.83 | SYK (0.41) | SYK | |
| SCHEMBL4090459 | 0.83 | CFD (0.41) | CFDTMIGD3HDAC6SYKEPHB4 | |
| SCHEMBL13771501 | 0.81 | CFD (0.44) | CFDTMIGD3HDAC6EPHB4 | |
| SCHEMBL104651 | 0.81 | HDAC1 (0.38) | HDAC1ROCK1 | |
| SCHEMBL2992603 | 0.80 | ALDH1A1 (0.46) | CFDTMIGD3EPHB4 | |
| SCHEMBL13765448 | 0.78 | BTK (0.46) | HDAC6HDAC1 | |
| SCHEMBL4090219 | 0.77 | CFD (0.42) | CFDTMIGD3HDAC6EPHB4 | |
| SCHEMBL103354 | 0.73 | ADORA1 (0.38) | HDAC1 | |
| SCHEMBL103863 | 0.73 | ROCK2 (0.42) | HDAC1ROCK1 | |
| SCHEMBL13893957 | 0.70 | ROCK1 (0.45) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| CN-101952283-B | Imidazo [1,2-a ] pyridine and imidazo [1,2-b ] pyridazine derivatives | HOFFMANN LA ROCHE | 2013-04-17 | — | — | CN | disclosed |
| CN-101952283-A | Novel imidazo [1,2-a ] pyridine and imidazo [1,2-b ] pyridazine derivatives | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CFD 3770/4885TMIGD3 4224/4885HDAC6 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.